Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Square Pharmaceuticals's FCF Yield % or its related term are showing as below:
DHA:SQURPHARMA'
s FCF Yield % Range Over the Past 10 Years
Min: 1.51 Med: 4.02 Max: 8.55
Current: 7.34
During the past 13 years, the highest FCF Yield % of Square Pharmaceuticals was 8.55%. The lowest was 1.51%. And the median was 4.02%.
DHA:SQURPHARMA's FCF Yield % is ranked better than 81.26% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 0.78
vs DHA:SQURPHARMA: 7.34
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Square Pharmaceuticals FCF Yield % Related Terms
Square Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:SQURPHARMA vs ZTS, UTHR: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Square Pharmaceuticals FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Square Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Square Pharmaceuticals (DHA:SQURPHARMA) has a FCF Yield % of 7.34 as of Sep. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Square Pharmaceuticals and its competitors. This is 83% above median its historical median of 4.02. Over the past decade, Square Pharmaceuticals' FCF Yield % has ranged from 1.51 to 8.55. According to the industry distribution chart, Square Pharmaceuticals ranks #188 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 18.7%.
Is Square Pharmaceuticals' FCF Yield % too high?
Square Pharmaceuticals' current FCF Yield % of 7.34 is 83% above median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 8.55. The Drug Manufacturers industry median FCF Yield % is 0.78. Square Pharmaceuticals' value of 7.34 is 841% above this industry median. Based on the distribution chart, Square Pharmaceuticals ranks #188 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Square Pharmaceuticals ranks #188 out of 1003 companies for FCF Yield %. This places Square Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.78. Square Pharmaceuticals' value of 7.34 is 841% above this benchmark. Historically, Square Pharmaceuticals' own FCF Yield % has ranged from 1.51 to 8.55 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 0.78, Square Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.78, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Square Pharmaceuticals's current FCF Yield % of 7.34 is 841% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Square Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Square Pharmaceuticals's current FCF Yield % is 7.34, which is 83% above median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current FCF Yield % is 7.34, which is 83% above median its 10-year median of 4.02 and 841% above the Drug Manufacturers industry median of 0.78. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current FCF Yield % is 7.34 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued.
The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96.
GuruFocus considers Square Pharmaceuticals to be Fairly Valued.
Key valuation signals for DHA:SQURPHARMA:
FCF Yield %: 7.34 (83% above median its 10-year median of 4.02)
GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
Industry Position: 841% above the Drug Manufacturers median (#188 of 1003)
No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score
Get the complete analysis for DHA:SQURPHARMA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:SQURPHARMA has been successfully added to your 
